Short Interest in Appili Therapeutics Inc. (OTCMKTS:APLIF) Decreases By 17.2%

Appili Therapeutics Inc. (OTCMKTS:APLIF) was the recipient of a large decline in short interest in the month of March. As of March 31st, there was short interest totalling 100,300 shares, a decline of 17.2% from the March 15th total of 121,200 shares. Approximately 0.1% of the company’s shares are short sold. Based on an average trading volume of 203,900 shares, the short-interest ratio is currently 0.5 days.

Appili Therapeutics Stock Up 12.7 %

Shares of Appili Therapeutics stock opened at $0.02 on Monday. The firm has a market cap of $3.01 million, a PE ratio of -1.24 and a beta of -0.54. Appili Therapeutics has a fifty-two week low of $0.01 and a fifty-two week high of $0.04. The business’s fifty day moving average is $0.02 and its two-hundred day moving average is $0.02.

About Appili Therapeutics

Appili Therapeutics Inc, a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis.